Evidence map›Paper›PMID 42291912›Full record

ReviewCureus2026

Myeloperoxidase Antineutrophil Cytoplasmic Antibody (MPO-ANCA)-Associated Usual Interstitial Pneumonia: Pathogenic Mechanisms, Diagnostic Challenges, and Clinical Implications.

Stephanie Johanna Chon Pineda, Mariana Baron-Anaya, Valeria Arroyo-Cruz, Ana-Paola Puente-Gutu, Alvaro Paul Calvo-Cantú, Dante Arroyo-Cruz, María Fernanda Aguirre Quintero, Alfonso Sandoval, Ashley Guzmán Velázquez, José Emiliano González Flores

Abstract readReview
In one paragraph

Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Stephanie Johanna Chon PinedaSchool of Medicine and Health Sciences, Tecnológico de Monterrey, Campus Ciudad de México, Mexico City, MEX.
Mariana Baron-AnayaFaculty of Health Sciences School of Medicine, Universidad Panamericana, Mexico City, MEX.
Valeria Arroyo-CruzSchool of Medicine and Health Sciences, Tecnológico de Monterrey, Campus Ciudad de México, Mexico City, MEX.
Ana-Paola Puente-GutuSchool of Medicine and Health Sciences, Tecnológico de Monterrey, Campus Ciudad de México, Mexico City, MEX.
Alvaro Paul Calvo-CantúSchool of Medicine and Health Sciences, Tecnológico de Monterrey, Campus Ciudad de México, Mexico City, MEX.
Dante Arroyo-CruzSchool of Medicine and Health Sciences, Tecnológico de Monterrey, Campus Ciudad de México, Mexico City, MEX.
María Fernanda Aguirre QuinteroSchool of Medicine and Health Sciences, Tecnológico de Monterrey, Campus Ciudad de México, Mexico City, MEX.
Alfonso SandovalSchool of Medicine and Health Sciences, Tecnológico de Monterrey, Campus Ciudad de México, Mexico City, MEX.
Ashley Guzmán VelázquezSchool of Medicine, Universidad Regional del Sureste, Oaxaca, MEX.
José Emiliano González FloresMedical Research and Academic Mentorship, ShareTheMed Research Group, Mexico City, MEX.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Usual interstitial pneumonia (UIP) has traditionally been regarded as synonymous with idiopathic pulmonary fibrosis (IPF) in the absence of an identifiable cause. However, emerging evidence demonstrates that a subset of patients with a UIP pattern exhibit myeloperoxidase antineutrophil cytoplasmic antibodies (MPO-ANCAs), suggesting a distinct and evolving clinical phenotype at the intersection of fibrotic lung disease and systemic autoimmunity. This structured narrative review aims to synthesize current evidence regarding the clinical, diagnostic, and therapeutic implications of MPO-ANCA-associated UIP. Preferred Reporting Items for Systematic Reviews and Meta-Analyses-like methodology was employed to identify and select relevant studies from PubMed (MEDLINE) and Google Scholar published between 2020 and 2026. After screening and eligibility assessment, 18 studies were included in the qualitative synthesis. Data were extracted on clinical presentation, radiological features, serological findings, therapeutic strategies, and outcomes. The available evidence indicates that pulmonary fibrosis may precede or coexist with ANCA-associated vasculitis, particularly microscopic polyangiitis, supporting the concept of UIP as a potential early or lung-dominant manifestation of systemic disease. This phenotype is characterized by a dual trajectory, combining progressive fibrosis with the risk of severe vasculitic complications such as diffuse alveolar hemorrhage. Radiological findings alone are insufficient for differentiation, highlighting the importance of MPO-ANCA testing for early phenotyping. Therapeutic management remains challenging due to the lack of standardized guidelines, requiring individualized and multidisciplinary approaches that balance antifibrotic and immunosuppressive strategies. MPO-ANCA-associated UIP should be recognized as a distinct and dynamic clinical entity with significant diagnostic and prognostic implications. Early identification and structured follow-up are essential to optimize outcomes and guide timely therapeutic interventions.

Indexed as

anca-associated vasculitisinterstitial lung diseasemicroscopic polyangiitismpo-ancapulmonary fibrosisusual interstitial pneumonia

Identifiers

PMID42291912
PMCPMC13256471

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.